Management Team
Mingdong Zhou, Ph.D.
Founder, Chief Executive Officer & Chief Scientist
Dr. Zhou is the founder, CEO and Chief Scientist of Zensun. Dr. Zhou earned his B.S. in biology from Fudan University in 1982 and his Ph.D. in cellular and molecular biology from New York State University in 1992. After he completed postdoctoral research training at the University of California, San Diego in 1996, he moved to Sydney, Australia, where he headed the Cell Signaling Laboratory of the Victor Chang Cardiac Research Institute. He discovered important effects of neuregulins in maintaining cardiomyocyte structure and function, as well as the fact that ErbB2/ErbB3 hetero-dimerization is essential for tumor development. Dr. Zhou has authored more than 30 original research papers in PNAS, JACC, JBC, Circulation Research, and other international journals. He has applied for 174 patents, 61 of which have been granted, including 41 world-wide and 20 patents in China. In 2000, Dr. Zhou returned to China and founded Zensun (Shanghai) Sci. & Tech. Co., Ltd. Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. The current pipeline includes cardiovascular disease treatment, anti-cancer drugs, and treatments for energy metabolism disorders. The first-in-class drug Neucardin™, which addresses wholly innovative targets and mechanisms, is now in phase III clinical trials and will bring revolutionary innovations in cardiomyocyte therapy. After more than ten years of research and development, Zensun’s product line of innovative drugs and medical instruments with short, medium, or long term horizons for commercialization is ready to begin appearing in the global market, and Zensun will become an integrated company doing research, production, and sales.
Zhenggang Jiang, Ph.D.
Executive Vice President, Business Development, Intellectual Property, Legal Affairs, and Strategic Planning
Dr. Jiang joined Zensun in 2008, where he was Group Leader of R&D, Senior Researcher of IP, and Executive Vice President during the past ten years at Zensun. Now, he is taking responsibility for a wide range of tasks, including business development, intellectual property, legal affairs and strategic planning. Dr. Jiang earned his Ph.D. degree at the Medical School of Fudan University with a major in immunology. He has authored more than 20 research papers in international journals.
Cangjing Yang, Ph.D.
Senior Vice President, Industrialization
Dr. Yang received his Ph.D. degree in Genetics from the School of Life Sciences, Fudan University. With solid experience in hormone signaling transduction pathways and four published SCI papers, Dr. Yang leads the company’s pre-clinical research of oncotherapy drugs and industrialization projects for Zensun’s drugs & medical devices.
Chen Zhuge, CFO
Chen Zhuge graduated from Peking University in 2001. He has more than 15 years of leadership and finance experience in both private companies and multinational corporations, such as P&G, Roland Berger, and Suntech, etc. He has in-depth knowledge and experience in Finance Management, Investment, M&A, and Strategic Planning.
Xiuhua Zhang
Senior Vice President, Secretary of the Board
Ms. Zhang has served in Zensun since 2002, where she was responsible for fundamental research, grant applications, and during the past years has been in charge of administration and human resources. She has now taken responsibility as Secretary of the Board and is also in charge of investor relationships. She received her Masters in molecular immunology from East China Normal University.
Jacky Wu
Vice President, Sales and Marketing
Mr. Wu holds his Bachelor’s degree from Shanghai Second Medical University, where he majored in Clinical Medicine. He has 20 years of healthcare industry experience working for multinational companies including Schering-Plough, Abbott, and Baxter. He is now overseeing sales and marketing in Zensun.
Xiangge Bai
Vice President, Legal Affairs
Vice President, Legal Affairs Mr. Bai has more than 15 years of experience in general corporate matters as well expertise in breadth of compliance and governance. He has previously worked for several renowned pharmaceutical companies in China, including public companies listed in the Chinese or U.S. stock markets. He received his Bachelor’s degree from the Law School of Peking University in 2000. He is now in charge of legal affairs and risk control.
Ting Dai
Vice President, Administration, Human Resource and Internal Control
Ms. Dai obtained her EMBA from Shanghai University of Finance and Economics. She joined Zensun in 2005, with extensive operational and managerial experience in financial planning and analysis, accounting, and treasury. In her current position as vice president, Ms. Dai has responsibility for administration, human resources and internal control.
Yiwen Chen .
Vice President, Business Development
Dr. Chen received his Ph.D. in biomedical sciences from the University of Macau. With his solid experience in biomedical research, drug quality control and assessment, project management, and eight published papers in Science, Dr. Chen is now focusing on Zensun’s business development and project cooperation. He is also a member of the American Chemical Society (ACS).
Xiaorui Wang, Ph.D.
Vice President, Regulatory Affairs and Clinical Development
Dr. Wang graduated from National University of Singapore with a Ph.D. in biochemistry in 2013. Before joining Zensun, she worked at Singapore Bioimaging Consortium, Agency for Science, Technology, and Research (A*STAR) from 2007 to 2014 as a senior research officer and worked on diabetes and obesity area. Her current role covers regulatory affairs and clinical development.
Qinghe Lok, Ph.D.
Deputy Vice President, Preclinical Pharmacology Research
Dr. Lok received his Ph.D. in neuropharmacology from Shanghai Jiaotong University in 2014. From June 2006 to June 2007, he worked as a chemist at Chemlab (Malaysia). From May 2014 to May 2016, he was a postdoctoral fellow in the department of biology (neurology) of Shanghai Jiaotong University. He joined Zesun in 2016, currently serving as Deputy Vice President of the pharmaceutical department, responsible for the preclinical pharmacology research of new drugs.
Bing Lin, Ph.D.
President, Zensun USA
Dr. Bing Lin joined Zensun USA in 2012. He has more than 14-year industrial experience in biotechnology and pharmaceutical companies on protein science and CMC. Before joining Zensun USA, he served as Director of Protein Chemistry in Anaphore and leaded a team for protein production, purification, characterization and CMC.  Prior to that, he held lead positions in Novartis GNF as Investigator II and in Alexion Pharmaceuticals as Senior Scientist. Dr. Lin earned his Ph.D. from Kansas State University and the Certificate for Regulatory Affairs Essentials from University of California at San Diego.
Lei Zhang, Ph.D.
Vice President, Zensun USA, Global Clinical Development & Operations
Dr. Zhang serves as VP of Global Clinical Development & Operations at Zensun USA overseeing global clinical studies. Dr. Lei Zhang has over 15 years of experience in clinical & medical affairs that span across the medical device, biotechnology, and diagnostic industries. Prior to Zensun, Dr. Zhang held management positions in Clinical & Medical Affairs and R & D at Alere, Cytori Therapeutics, Inovio Biomedical, Halozyme Therapeutics and Genetronics, Inc. Dr. Zhang earned her Ph.D. in from Friedrich-Shiller Univ. in Germany.
 
Clinical Trials Recruiting Participants